Cite
Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
MLA
Maurel J, et al. “Imatinib plus Low-Dose Doxorubicin in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to High-Dose Imatinib: A Phase I-II Study by the Spanish Group for Research on Sarcomas.” Cancer (0008543X), vol. 116, no. 15, Aug. 2010, pp. 3692–701. EBSCOhost, https://doi.org/10.1002/cncr.25111.
APA
Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, Martínez-Trufero J, Ramón Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia Del Muro X, de Alava E, Maurel, J., Martins, A. S., Poveda, A., López-Guerrero, J. A., Cubedo, R., Casado, A., Martínez-Trufero, J., & Ramón Ayuso, J. (2010). Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer (0008543X), 116(15), 3692–3701. https://doi.org/10.1002/cncr.25111
Chicago
Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, Martínez-Trufero J, et al. 2010. “Imatinib plus Low-Dose Doxorubicin in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to High-Dose Imatinib: A Phase I-II Study by the Spanish Group for Research on Sarcomas.” Cancer (0008543X) 116 (15): 3692–3701. doi:10.1002/cncr.25111.